A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

NCT ID: NCT06471361

Last Updated: 2025-09-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-27
• Study Completion Date: 2025-02-03

Brief Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.

Conditions

Generalized Myasthenia Gravis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Zilucoplan-auto-injector (ZLP-AI)

Study participants will self-administer zilucoplan (ZLP) based on their body weight using auto-injector (AI).

Group Type: EXPERIMENTAL

Zilucoplan

Intervention Type: DRUG

Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.

Interventions

Zilucoplan

Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.

Intervention Type: DRUG

Other Intervention Names

RA101495

Eligibility Criteria

Inclusion Criteria

• Study participant is male or female and must be at least 18 years of age at the time of signing the informed consent form (ICF).
• Study participant must have a documented diagnosis of gMG, based on study participant's history and supported by previous evaluations.
• Study participant is currently participating in ZLP (zilucoplan) study RA101495-02.302 (NCT04225871) or is administering commercial ZLP on a stable dosing regimen for at least 1 month prior to Screening.
• Study participants on commercial ZLP need to receive ZLP per the approved local labeling.
• Study participant is considered reliable and capable of adhering to the study protocol (eg, able to understand and complete questionnaires and able to adhere to the visit schedule) according to the judgement of the Investigator.
• Study participant is willing and capable of self-administering ZLP using the zilucoplan-auto-injector (ZLP AI) according to the instructions for use (IFU), ie, does not have any visual, physical, or other disability or impairment that interferes with his/her capacity to self-administer; if the participant has a caregiver, he/she may assist the participant with the injection.
• Vaccination with a quadrivalent meningococcal vaccine and, where available, meningococcal serotype B vaccine at least 14 days prior to investigational medicinal product (IMP) administration, if not vaccinated within 3 years prior to the start of treatment. Booster vaccination(s) should also be administered as clinically indicated, according to the local standard of care, for participants who have been previously vaccinated against Neisseria meningitidis.
• Female participants of childbearing potential must have a negative urine pregnancy test prior to the first dose of study drug.
• Male and/or female study participants

1. A male participant must agree to use contraception during the Treatment Period and for 40 days after the last dose of study medication, and refrain from donating sperm during this period.

2. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

• Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance the Treatment Period and for 40 days after the last dose of study medication.
• Capable of giving signed informed which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion Criteria

• Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.
• Female participants who are breastfeeding, pregnant, or plan to become pregnant during the study.
• Study participant has a known hypersensitivity to any components of the study medication (and/or an investigational device) as stated in this protocol.
• Study participant has a clinically relevant active infection or a history of serious infection (resulting in hospitalization or requiring intravenous antibiotic treatment) within 6 weeks before Visit 1.
• Study participant has a history of meningococcal disease.
• Participant has previously participated in this study or participant has previously been assigned to treatment in a study of the medication under investigation in this study (except studies RA101495-02.201 (NCT03315130), RA101495-02.301 (NCT04115293), or RA101495-02.302 (NCT04225871), which are not excluded, unless the participant was required to withdraw from said studies for a safety reason which could reasonably recur).
• Participant has participated in another study of an IMP (and/or an investigational device) different from ZLP within the previous 3 months or 5 half-lives, whichever is longer, or is currently participating in another study of an IMP (and/or an investigational device).
• Current unstable liver or biliary disease at Screening (Visit 1), per Investigator assessment, defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: with exception of stable hepatobiliary conditions (including Gilbert's syndrome, asymptomatic gallstones).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

UCB Biopharma SRL

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273

Locations

Dv0013 50628

New Haven, Connecticut, United States

Dv0013 50634

Tampa, Florida, United States

Dv0013 50648

Columbia, Missouri, United States

Dv0013 50556

Chapel Hill, North Carolina, United States

Dv0013 50635

Columbus, Ohio, United States

Dv0013 50555

Austin, Texas, United States

Dv0013 50636

Greenfield, Wisconsin, United States

Dv0013 40609

Katowice, , Poland

Dv0013 40759

Krakow, , Poland

Dv0013 40605

Poznan, , Poland

Dv0013 40760

Oxford, , United Kingdom

Countries

United States; Poland; United Kingdom

Other Identifiers

U1111-1302-4369

Identifier Type: OTHER

Identifier Source: secondary_id

2023-508287-30

Identifier Type: REGISTRY

Identifier Source: secondary_id

DV0013

Identifier Type: -

Identifier Source: org_study_id